Mustafa Arisoy
Mustafa Arisoy has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Mehtap Saydam
Drogsan İlaçları Ar-Ge
2 shared publications - Emel Dogan Kurtoglu
Novagenix Bioanalytical Drug R&D Centre, 06750 Ankara, Turkey
1 shared publication - Fatma Kaynak Onurdağ
Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Trakya University, 22030 Edirne, Türkiye
1 shared publication Gökçe Demiray
Novagenix Bioanalytical Drug R&D Centre, Balikhisar, Ozal Avenue No:664, Akyurt, ANKARA, 06970, TURKEY
1 shared publication- Mustafa Çelebier
Department of Analytical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara 06230, Türkiye
1 shared publication Onursal Sağlam
Novagenix Bioanalytical Drug R&D Centre, Balikhisar, Ozal Avenue No:664, Akyurt, ANKARA, 06970, TURKEY
1 shared publication
Latest Publications
- 27 October 2026
- Published by Cumhuriyet University in Cumhuriyet Science Journal
- Vol. 47 (5) , 950-960
Development and Validation of a Gradient RP-HPLC Method Using a Risk-Based AQbD Framework for the Simultaneous Determination of Paracetamol, Phenylephrine Hydrochloride, Chlorpheniramine Maleate, and Oxolamine Citrate in an Effervescent Sachet Formulation
A gradient RP-HPLC method was developed and validated for the simultaneous determination of paracetamol, phenylephrine hydrochloride, oxolamine citrate, and chlorpheniramine maleate in an effervescent sachet formulation. A structured, risk-based approach was applied during analytical procedure development to identify potential sources of variability and to select method parameters for further experimental evaluation. Based on the risk assessment, flow rate, column temperature, and detection wavelength were selected and evaluated by deliberate univariate variation around their nominal conditions. Separation was achieved on a reversed-phase C18 column using gradient elution with phosphate buffer (pH 4.5) and acetonitrile. Phenylephrine hydrochloride, oxolamine citrate, and chlorpheniramine maleate were monitored at 224 nm, whereas paracetamol was monitored at 300 nm. The method was validated according to ICH Q2(R2) for specificity, linearity, range, accuracy, precision, and robustness. Linearity was demonstrated over the investigated concentration ranges, with coefficients of determination (R²) greater than 0.999 for all analytes. Mean recoveries ranged from 98.24% to 101.01%, and the intermediate precision RSD% values were below 2.0%. No interference from the placebo was observed at the analyte retention times. Adequate chromatographic performance was maintained under the investigated deliberate variations in method parameters. The method was successfully applied to the simultaneous assay of the four active ingredients in the investigated commercial effervescent sachet formulation.
- 27 October 2026
- Published by Cumhuriyet University in Cumhuriyet Science Journal
- Vol. 47 (5) , 950-960
Development and Validation of a Gradient RP-HPLC Method Using a Risk-Based AQbD Framework for the Simultaneous Determination of Paracetamol, Phenylephrine Hydrochloride, Chlorpheniramine Maleate, and Oxolamine Citrate in an Effervescent Sachet Formulation
A gradient RP-HPLC method was developed and validated for the simultaneous determination of paracetamol, phenylephrine hydrochloride, oxolamine citrate, and chlorpheniramine maleate in an effervescent sachet formulation. A structured, risk-based approach was applied during analytical procedure development to identify potential sources of variability and to select method parameters for further experimental evaluation. Based on the risk assessment, flow rate, column temperature, and detection wavelength were selected and evaluated by deliberate univariate variation around their nominal conditions. Separation was achieved on a reversed-phase C18 column using gradient elution with phosphate buffer (pH 4.5) and acetonitrile. Phenylephrine hydrochloride, oxolamine citrate, and chlorpheniramine maleate were monitored at 224 nm, whereas paracetamol was monitored at 300 nm. The method was validated according to ICH Q2(R2) for specificity, linearity, range, accuracy, precision, and robustness. Linearity was demonstrated over the investigated concentration ranges, with coefficients of determination (R²) greater than 0.999 for all analytes. Mean recoveries ranged from 98.24% to 101.01%, and the intermediate precision RSD% values were below 2.0%. No interference from the placebo was observed at the analyte retention times. Adequate chromatographic performance was maintained under the investigated deliberate variations in method parameters. The method was successfully applied to the simultaneous assay of the four active ingredients in the investigated commercial effervescent sachet formulation.
- 15 August 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (11) , 3149-3154
A Study to Compare Bioequivalence Approach Between FDA and EMA in a Highly Variable Drug: Pinaverium Bromide Film Tablets
- 15 August 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (11) , 3149-3154
A Study to Compare Bioequivalence Approach Between FDA and EMA in a Highly Variable Drug: Pinaverium Bromide Film Tablets
- Open Access
- 1 December 2013
- Published by Walter de Gruyter GmbH in Zeitschrift für Naturforschung C
- Vol. 68 (11-12) , 453-460
Novel Benzoxazoles: Synthesis and Antibacterial, Antifungal, and Antitubercular Activity against Antibiotic-Resistant and -Sensitive Microbes
A new series of 5-(p-substituted benzamido/phenylacetamido)-2-(p-tert-butylphenyl)benzoxazole derivatives were synthesized and evaluated for their antibacterial, antifungal, and antimycobacterial activities against antibiotic-resistant and -sensitive Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, and Mycobacterium tuberculosis as well as against Candida albicans and Candida krusei. The compounds possessed broad-spectrum activity against all of the tested Gram-positive and Gram-negative bacteria and yeasts, their minimum inhibitory concentrations (MICs) ranging between 16 - 128 μg/ml. One compound exhibited significant antibacterial activity (16 μg/ml) against an antibioticresistant Enterococcus faecalis isolate, having twice the potency of the compared standard drugs vancomycin and gentamycin sulfate. The compounds also showed moderate antitubercular activity with MIC values between 8 - 128 μg/ml against Mycobacterium tuberculosis and its clinical isolate.
- 1 December 2013
- Published by Walter de Gruyter GmbH in Zeitschrift für Naturforschung C
- Vol. 68 (11-12) , 453-460
Open AccessNovel Benzoxazoles: Synthesis and Antibacterial, Antifungal, and Antitubercular Activity against Antibiotic-Resistant and -Sensitive Microbes
A new series of 5-(p-substituted benzamido/phenylacetamido)-2-(p-tert-butylphenyl)benzoxazole derivatives were synthesized and evaluated for their antibacterial, antifungal, and antimycobacterial activities against antibiotic-resistant and -sensitive Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, and Mycobacterium tuberculosis as well as against Candida albicans and Candida krusei. The compounds possessed broad-spectrum activity against all of the tested Gram-positive and Gram-negative bacteria and yeasts, their minimum inhibitory concentrations (MICs) ranging between 16 - 128 μg/ml. One compound exhibited significant antibacterial activity (16 μg/ml) against an antibioticresistant Enterococcus faecalis isolate, having twice the potency of the compared standard drugs vancomycin and gentamycin sulfate. The compounds also showed moderate antitubercular activity with MIC values between 8 - 128 μg/ml against Mycobacterium tuberculosis and its clinical isolate.